Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275197 · ClinicalTrials.gov registry record · Phase 2
A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 262
- Enrollment target
NCT00275197 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 262 participants.
The verdict
NCT00275197, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 262 participants
- Enrollment target
Study Summary
The major purpose of the study is to help determine whether giving the combination of Elzasonan with Zoloft to people with depression is a better treatment than taking Zoloft alone. This study will also compare the safety and tolerability of Elzasonan and Zoloft combination to Zoloft alone or placebo.
Interventions
- DRUG Placebo
- DRUG Sertraline
- DRUG Sertraline and Elzasonan Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275197
The ClinicalTrials.gov registry entry for NCT00275197 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00275197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00275197 about?
NCT00275197 is a clinical study titled "A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)". The major purpose of the study is to help determine whether giving the combination of Elzasonan with Zoloft to people with depression is a better treatment than taking Zoloft alone. This study will also compare the safety and tolerability of Elzasonan and Zoloft combination to Zoloft alone or placeb...
What is the current status of trial NCT00275197?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 262 participants. The study started on 2005-12. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00275197?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG), Sertraline and Elzasonan Combination (DRUG).
Who is sponsoring clinical trial NCT00275197?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.